These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
190 related items for PubMed ID: 37294957
1. Post-transplant lymphoproliferative disease in children, adolescents, and young adults. Gross TG, Rubinstein JD. Hematol Oncol; 2023 Jun; 41 Suppl 1():48-56. PubMed ID: 37294957 [Abstract] [Full Text] [Related]
2. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation. Lindsay J, Yong MK, Greenwood M, Kong DCM, Chen SCA, Rawlinson W, Slavin M. Rev Med Virol; 2020 Jul; 30(4):e2108. PubMed ID: 32301566 [Abstract] [Full Text] [Related]
3. Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults. Rubinstein J, Toner K, Gross T, Wistinghausen B. Best Pract Res Clin Haematol; 2023 Mar; 36(1):101446. PubMed ID: 36907642 [Abstract] [Full Text] [Related]
6. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation. Liu QF, Fan ZP, Luo XD, Sun J, Zhang Y, Ding YQ. Transpl Infect Dis; 2010 Aug 01; 12(4):284-91. PubMed ID: 20345506 [Abstract] [Full Text] [Related]
9. Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment. Overkamp M, Granai M, Bonzheim I, Steinhilber J, Schittenhelm J, Bethge W, Quintanilla-Martinez L, Fend F, Federmann B. Virchows Arch; 2021 Jun 01; 478(6):1135-1148. PubMed ID: 33324999 [Abstract] [Full Text] [Related]
10. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. Naik S, Riches M, Hari P, Kim S, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, Chhabra S, Daly A, Storek J, Ustun C, Diaz MA, Cerny J, Beitinjaneh A, Yared J, Brown V, Page K, Dahi PB, Ganguly S, Seo S, Chao N, Freytes CO, Saad A, Savani BN, Woo Ahn K, Boeckh M, Heslop HE, Lazarus HM, Auletta JJ, Kamble RT. Transpl Infect Dis; 2019 Oct 01; 21(5):e13145. PubMed ID: 31301099 [Abstract] [Full Text] [Related]
11. Risk factors evaluation of post-transplant lymphoproliferative disorders after allogeneic haematopoietic stem cell transplantation with comparison between paediatric and adult. Chen DB, Liu XY, Kong FZ, Jiang Q, Shen DH. J Clin Pathol; 2021 Nov 01; 74(11):697-703. PubMed ID: 34011618 [Abstract] [Full Text] [Related]
13. Late-onset posttransplant Epstein-Barr virusrelated lymphoproliferative disease after cord blood transplantation for chronic active Epstein Barr virus infection: A case report. Yamamoto M, Shindo M, Funayama T, Sumi C, Saito T, Toki Y, Hatayama M, Imadome KI, Mizukami Y, Okumura T. Medicine (Baltimore); 2022 Mar 25; 101(12):e29055. PubMed ID: 35357349 [Abstract] [Full Text] [Related]
16. The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients. Wareham NE, Mocroft A, Sengeløv H, Da Cunha-Bang C, Gustafsson F, Heilmann C, Iversen M, Kirkby NS, Rasmussen A, Sørensen SS, Lundgren JD, MATCH in PERSIMUNE study group. J Cancer Res Clin Oncol; 2018 Aug 25; 144(8):1569-1580. PubMed ID: 29804164 [Abstract] [Full Text] [Related]
17. Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation. Meyer SC, Medinger M, Halter JP, Baldomero H, Hirsch HH, Tzankov A, Dirnhofer S, Passweg JR, Tichelli A. Hematology; 2014 Jul 25; 19(5):280-5. PubMed ID: 24074746 [Abstract] [Full Text] [Related]
18. Expert Consensus on the Characteristics of Patients with Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) for Whom Standard-Dose Chemotherapy May be Inappropriate: A Modified Delphi Study. Chaganti S, Barlev A, Caillard S, Choquet S, Cwynarski K, Friedetzky A, González-Barca E, Sadetsky N, Schneeberger S, Thirumalai D, Zinzani PL, Trappe RU. Adv Ther; 2023 Mar 25; 40(3):1267-1281. PubMed ID: 36681739 [Abstract] [Full Text] [Related]